ClinicalTrials.gg
CompletedNCT01332968Updated Aug 11, 2022Results posted

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

A Phase 3 interventional study of Obinutuzumab and Cyclophosphamide in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 183 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,401
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. obinutuzumab · Lymphoma, Non-Hodgkin.

Enrollment
Largest of 15
1,401 · median 41
Started
2011
the only one that year
Phase 3
2 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
5 of 15
Hoffmann-La Roche

Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, this one has the largest enrollment, is the only one that started in 2011, is one of 2 in phase 3, and was the 3rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response [CR] or partial response [PR]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cluster of differentiation 20 (CD20)-positive indolent B-cell non-Hodgkin's lymphoma (follicular lymphoma or splenic, nodal or extranodal marginal zone lymphoma)
  • Stage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to [>/=] 7 centimeters [cm])
  • For participants with follicular lymphoma: requirement for treatment according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria
  • For participants with symptomatic splenic, nodal, or non-gastric extranodal marginal zone lymphoma: disease that is de novo or has following local therapy (i.e. surgery or radiotherapy) and requires therapy as assessed by the investigator
  • At least one bi-dimensionally (greater than [>] 2 cm in its largest dimension by computed tomography [CT] scan or magnetic resonance imaging [MRI])
  • (ECOG) performance status of 0, 1 or 2
  • Adequate hematologic function

Exclusion criteria

Exclusion Criteria:

  • Central nervous system lymphoma, lymphoma, or histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
  • Grade 3b follicular lymphoma, small lymphocytic lymphoma or Waldenström's macroglobulinaemia
  • Ann Arbor Stage I disease
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • Known to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol
  • For participants with follicular lymphoma: prior treatment for non-Hodgkin's lymphoma with chemotherapy, immunotherapy, or radiotherapy
  • For participants with non-follicular lymphoma: prior treatment with chemotherapy or immunotherapy
  • Regular treatment with during the 4 weeks prior to the start of Cycle 1
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
  • For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): (LVEF) less than (\<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogram
  • History of prior other with the exception of curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study
  • Known active infection, or major episode of infection within 4 week prior to the start of Cycle 1
  • Vaccination with a within 28 days prior to randomization
  • Recent major surgery (within 4 weeks prior to start of Cycle 1), other than for diagnosis
  • Abnormal laboratory values as defined by protocol for creatinine, , (AST) or alanine transaminase (ALT), total , international normalized ration (), partial thromboplastin time (PTT) or activated partial thromboplastin time (aPPT), unless these abnormalities are due to underlying lymphoma
  • Positive test results for (HIV), human T-lymphotropic virus 1 (HTLV1), or chronic
  • Pregnant or lactating women
  • \<12 months
  • Participation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1 and during study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,401 participants (actual)

Study arms

  • Active comparator
    Rituximab+Chemotherapy

    Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.

    Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Bendamustine · Drug: Rituximab

  • Experimental
    Obinutuzumab+Chemotherapy

    Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.

    Drug: Obinutuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Bendamustine

Interventions

  • Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.

    Also known as: GA101; RO5072759

  • Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

  • Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

  • Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.

  • Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.

  • Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.

  • Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

    Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).

    Time frame: Baseline up to data cut-off (up to approximately 4 years and 7 months)

Secondary outcomes

  1. Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

    Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).

    Time frame: Baseline up to final analysis (up to 10 years)

  2. Progression-Free Survival in the Overall Study Population, Investigator-Assessed

    Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.

    Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)

  3. Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed

    Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available.

    Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)

  4. Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)

    Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.

    Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)

  5. Overall Response (Follicular Lymphoma Population), Investigator-Assessed

    Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)

  6. Overall Response (Overall Study Population), Investigator-Assessed

    Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)

  7. Complete Response (Follicular Lymphoma Population), Investigator-Assessed

    Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)

  8. Complete Response (Overall Study Population), Investigator-Assessed

    Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)

  9. Overall Response (Follicular Lymphoma Population), IRC-Assessed

    Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)

  10. Overall Response (Overall Study Population), IRC-Assessed

    Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)

  11. Complete Response (Follicular Lymphoma Population), IRC-Assessed

    Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)

  12. Complete Response (Overall Study Population), IRC-Assessed

    Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

    Time frame: Baseline up to end of induction period (up to approximately 7 months)]

  13. Overall Survival (Follicular Lymphoma Population)

    Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.

    Time frame: Baseline up to 10 years

  14. Overall Survival (Overall Study Population)

    Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.

    Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)

  15. Event-Free Survival (Follicular Lymphoma Population)

    Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event.

    Time frame: Baseline up to 10 years

  16. Event-Free Survival (Overall Study Population)

    Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.

    Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)

  17. Disease-Free Survival (Follicular Lymphoma Population)

    Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.

    Time frame: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)

  18. Disease-Free Survival (Overall Study Population)

    Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.

    Time frame: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)

  19. Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed

    DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.

    Time frame: From first occurrence of documented CR or PR to data cut-off (up to approximately 5 years and 2 months)

  20. Duration of Response (DOR) (Overall Study Population), Investigator-Assessed

    DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.

    Time frame: From first occurrence of documented CR or PR to data cut-off (up to approximately 4 years and 7 months)

  21. Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)

    Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.

    Time frame: Baseline up to 10 years

  22. Time to Next Anti-Lymphoma Treatment (Overall Study Population)

    Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.

    Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)

  23. Percentage of Participants With Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline up to 10 years

  24. Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)

    FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period.

    Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

  25. Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)

    The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.

    Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

  26. Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)

    The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.

    Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

  27. Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)

    The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.

    Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

  28. Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase

    The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs.

    Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

  29. Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase

    The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit.

    Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

  30. Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase

    The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit.

    Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 after Day 1 of last induction cycle, Follow-up: every year for up to data cut-off (up to 5 years and 2 months)

07

Results

Posted Jun 7, 2017

Participant flow

The study was conducted at 177 centers in 18 countries.

Induction Period
Participant flow — Induction Period
MilestoneRituximab+Chemotherapy - Induction PeriodObinutuzumab+Chemotherapy - Induction PeriodRituximab+Chemotherapy - Maintenance PeriodObinutuzumab+Chemotherapy - Maintenance PeriodRituximab+Chemotherapy - Observation PeriodObinutuzumab+Chemotherapy - Observation PeriodRituximab+Chemotherapy - Follow-Up PeriodObinutuzumab+Chemotherapy - Follow-Up Period
Started699702000000
Completed641646000000
Not completed5856000000
Withdrew: Adverse event2326000000
Withdrew: Death14000000
Withdrew: Non-compliance10000000
Withdrew: Other22000000
Withdrew: Physician decision61000000
Withdrew: Progressive disease157000000
Withdrew: Protocol violation34000000
Withdrew: Withdrawal by subject35000000
Withdrew: Randomised but not treated47000000
Maintenance/Observation Period
Participant flow — Maintenance/Observation Period
MilestoneRituximab+Chemotherapy - Induction PeriodObinutuzumab+Chemotherapy - Induction PeriodRituximab+Chemotherapy - Maintenance PeriodObinutuzumab+Chemotherapy - Maintenance PeriodRituximab+Chemotherapy - Observation PeriodObinutuzumab+Chemotherapy - Observation PeriodRituximab+Chemotherapy - Follow-Up PeriodObinutuzumab+Chemotherapy - Follow-Up Period
Started00612624121100
Completed00451475121000
Not completed001611490100
Withdrew: Adverse event0053660000
Withdrew: Death00560000
Withdrew: Lost to follow-up00120000
Withdrew: Non-compliance00430000
Withdrew: Other00470000
Withdrew: Physician decision0014190100
Withdrew: Progressive disease0072400000
Withdrew: Protocol violation00110000
Withdrew: Withdrawal by subject00750000
Follow-Up Period
Participant flow — Follow-Up Period
MilestoneRituximab+Chemotherapy - Induction PeriodObinutuzumab+Chemotherapy - Induction PeriodRituximab+Chemotherapy - Maintenance PeriodObinutuzumab+Chemotherapy - Maintenance PeriodRituximab+Chemotherapy - Observation PeriodObinutuzumab+Chemotherapy - Observation PeriodRituximab+Chemotherapy - Follow-Up PeriodObinutuzumab+Chemotherapy - Follow-Up Period
Started000000554602
Completed000000324367
Not completed000000230235
Withdrew: Adverse event00000004
Withdrew: Death0000002730
Withdrew: Lost to follow-up0000001115
Withdrew: Non-compliance00000049
Withdrew: Other0000001821
Withdrew: Physician decision0000001215
Withdrew: Progressive disease000000126106
Withdrew: Protocol violation00000010
Withdrew: Withdrawal by subject0000002932
Withdrew: No reason provided00000023

Outcome measures

PrimaryProgression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).

Time frame:
Baseline up to data cut-off (up to approximately 4 years and 7 months)
Reported as:
Number · percentage of participants with event
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed24.016.8
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.0012 · Hazard ratio (hr): 0.66 · 95% CI 0.51 to 0.85Stratified by chemotherapy regimen and Follicular Lymphoma International Prognostic Index (FLIPI) risk group.
SecondaryProgression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).

Time frame:
Baseline up to final analysis (up to 10 years)
Reported as:
Number · percentage of participants with event
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed40.634.3
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.0055 · Hazard ratio (hr): 0.77 · 95% CI 0.64 to 0.93Stratified by chemotherapy regimen and Follicular Lymphoma International Prognostic Index (FLIPI) risk group.
SecondaryProgression-Free Survival in the Overall Study Population, Investigator-Assessed

Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.

Time frame:
Baseline up to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Progression-Free Survival in the Overall Study Population, Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Progression-Free Survival in the Overall Study Population, Investigator-Assessed41.534.8
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.0028 · Hazard ratio (hr): 0.77 · 95% CI 0.65 to 0.91
SecondaryProgression-Free Survival (Follicular Lymphoma Population), IRC-Assessed

Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available.

Time frame:
Baseline up to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed23.518.0
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.0118 · Hazard ratio (hr): 0.72 · 95% CI 0.56 to 0.93
SecondaryProgression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)

Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.

Time frame:
Baseline up to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)24.618.4
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.0038 · Hazard ratio (hr): 0.71 · 95% CI 0.57 to 0.90
SecondaryOverall Response (Follicular Lymphoma Population), Investigator-Assessed

Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)
Reported as:
Number · percentage of participants with event
Overall Response (Follicular Lymphoma Population), Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET86.488.2
With PET81.285.5
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.30 · Absolute difference in %: 1.8 · 95% CI -2.02 to 5.68
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.17 · Absolute difference in %: 4.3 · 95% CI -1.8 to 10.5
SecondaryOverall Response (Overall Study Population), Investigator-Assessed

Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)
Reported as:
Number · percentage of participants with event
Overall Response (Overall Study Population), Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET85.787.3
With PET81.885.4
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.33 · Absolute difference in %: 1.6 · 95% CI -2.0 to 5.3
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.17 · Absolute difference in %: 3.5 · 95% CI -2.3 to 9.4
SecondaryComplete Response (Follicular Lymphoma Population), Investigator-Assessed

Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)
Reported as:
Number · percentage of participants with event
Complete Response (Follicular Lymphoma Population), Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET24.118.6
With PET56.762.0
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.02 · Absolute difference in %: -5.5 · 95% CI -10.2 to -0.78
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.32 · Absolute difference in %: 5.2 · 95% CI -2.8 to 13.3
SecondaryComplete Response (Overall Study Population), Investigator-Assessed

Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)
Reported as:
Number · percentage of participants with event
Complete Response (Overall Study Population), Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET23.318.4
With PET57.061.1
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.02 · Absolute difference in %: -4.9 · 95% CI -9.3 to 0.6
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.33 · Absolute difference in %: 4.1 · 95% CI -3.6 to 11.8
SecondaryOverall Response (Follicular Lymphoma Population), IRC-Assessed

Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Overall Response (OR) = CR + PR.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)
Reported as:
Number · percentage of participants with event
Overall Response (Follicular Lymphoma Population), IRC-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET88.091.3
With PET85.288.6
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.052 · Absolute difference in %: 3.3 · 95% CI -0.19 to 6.85
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.30 · Absolute difference in %: 3.3 · 95% CI -2.3 to 8.9
SecondaryOverall Response (Overall Study Population), IRC-Assessed

Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%; Overall Response (OR) = CR + PR.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)
Reported as:
Number · percentage of participants with event
Overall Response (Overall Study Population), IRC-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET86.789.9
With PET83.387.2
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.049 · Absolute difference in %: 3.2 · 95% CI -0.3 to 6.6
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.22 · Absolute difference in %: 3.9 · 95% CI -1.7 to 9.5
SecondaryComplete Response (Follicular Lymphoma Population), IRC-Assessed

Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)
Reported as:
Number · percentage of participants with event
Complete Response (Follicular Lymphoma Population), IRC-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET26.828.5
With PET59.771.4
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.58 · Absolute difference in %: 1.7 · 95% CI -3.5 to 6.8
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.006 · Absolute difference in %: 11.7 · 95% CI 3.9 to 19.4
SecondaryComplete Response (Overall Study Population), IRC-Assessed

Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.

Time frame:
Baseline up to end of induction period (up to approximately 7 months)]
Reported as:
Number · percentage of participants with event
Complete Response (Overall Study Population), IRC-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET26.327.1
With PET59.469.5
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.80 · Absolute difference in %: 0.7 · 95% CI -4.0 to 5.5
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.009 · Absolute difference in %: 10.1 · 95% CI 2.6 to 17.6
SecondaryOverall Survival (Follicular Lymphoma Population)

Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.

Time frame:
Baseline up to 10 years
Reported as:
Number · percentage of participants with event
Overall Survival (Follicular Lymphoma Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Overall Survival (Follicular Lymphoma Population)14.312.6
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.3577 · Hazard ratio (hr): 0.86 · 95% CI 0.63 to 1.18
SecondaryOverall Survival (Overall Study Population)

Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.

Time frame:
Baseline up to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Overall Survival (Overall Study Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Overall Survival (Overall Study Population)10.28.4
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.25 · Hazard ratio (hr): 0.82 · 95% CI 0.58 to 1.16
SecondaryEvent-Free Survival (Follicular Lymphoma Population)

Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event.

Time frame:
Baseline up to 10 years
Reported as:
Number · percentage of participants with event
Event-Free Survival (Follicular Lymphoma Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Event-Free Survival (Follicular Lymphoma Population)42.935.8
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.0015 · Hazard ratio (hr): 0.74 · 95% CI 0.62 to 0.89
SecondaryEvent-Free Survival (Overall Study Population)

Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.

Time frame:
Baseline up to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Event-Free Survival (Overall Study Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Event-Free Survival (Overall Study Population)30.622.6
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.0004 · Hazard ratio (hr): 0.69 · 95% CI 0.56 to 0.85
SecondaryDisease-Free Survival (Follicular Lymphoma Population)

Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.

Time frame:
From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Disease-Free Survival (Follicular Lymphoma Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Disease-Free Survival (Follicular Lymphoma Population)27.926.3
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · Hazard ratio (hr): 0.95 · 95% CI 0.71 to 1.27
SecondaryDisease-Free Survival (Overall Study Population)

Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Reported is the percentage of participants with event.

Time frame:
From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Disease-Free Survival (Overall Study Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Disease-Free Survival (Overall Study Population)14.911.2
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Hazard ratio (hr): 0.78 · 95% CI 0.50 to 1.19
SecondaryDuration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed

DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.

Time frame:
From first occurrence of documented CR or PR to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed39.333.3
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · Hazard ratio (hr): 0.76 · 95% CI 0.63 to 0.93
SecondaryDuration of Response (DOR) (Overall Study Population), Investigator-Assessed

DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.

Time frame:
From first occurrence of documented CR or PR to data cut-off (up to approximately 4 years and 7 months)
Reported as:
Number · percentage of participants with event
Duration of Response (DOR) (Overall Study Population), Investigator-Assessed
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Duration of Response (DOR) (Overall Study Population), Investigator-Assessed25.518.7
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Hazard ratio (hr): 0.69 · 95% CI 0.55 to 0.88
SecondaryTime to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)

Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.

Time frame:
Baseline up to 10 years
Reported as:
Number · percentage of participants with event
Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)34.826.6
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.001 · Hazard ratio (hr): 0.71 · 95% CI 0.58 to 0.87
SecondaryTime to Next Anti-Lymphoma Treatment (Overall Study Population)

Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.

Time frame:
Baseline up to data cut-off (up to approximately 5 years and 2 months)
Reported as:
Number · percentage of participants with event
Time to Next Anti-Lymphoma Treatment (Overall Study Population)
percentage of participants with eventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Time to Next Anti-Lymphoma Treatment (Overall Study Population)21.615.7
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.004 · Hazard ratio (hr): 0.70 · 95% CI 0.54 to 0.89
SecondaryPercentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline up to 10 years
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Percentage of Participants With Adverse Events99.699.9
SecondaryChange From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)

FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period.

Time frame:
Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Reported as:
Mean · units on a scale
Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)
units on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Physical Well-being (PW), Baseline23.36 ± 4.7723.14 ± 4.85
PW Change, Cycle 3, Day 1-0.91 ± 4.54-0.21 ± 4.59
PW Change, End Induction-0.06 ± 4.830.56 ± 5.14
PW Change, Maint Month 20.83 ± 4.761.42 ± 5.09
PW Change, Maint Month 121.14 ± 4.291.34 ± 4.74
PW Change, End Maint0.88 ± 4.541.33 ± 5.00
Social/Family Well-being , Baseline22.84 ± 4.9223.28 ± 4.77
S/FW Change, Cycle 3 Day 1-0.52 ± 4.03-0.67 ± 3.92
S/FW Change, End Induction-0.46 ± 4.77-0.56 ± 5.00
S/FW Change, Maint Month 2-0.39 ± 4.72-0.67 ± 4.68
S/FW Change, Maint Month 12-0.61 ± 5.56-0.97 ± 5.34
S/FW Change, End Maint-0.93 ± 5.67-0.71 ± 5.54
Emotional Well-being (EW), Baseline17.64 ± 4.1917.87 ± 4.13
EW Change, Cycle 3 Day 11.49 ± 3.401.35 ± 3.35
EW Change, End Induction1.16 ± 3.901.14 ± 3.87
EW Change, Maint Month 21.77 ± 3.881.49 ± 4.16
EW Change, Maint Month 121.45 ± 3.921.46 ± 3.88
EW Change, End Maint1.43 ± 3.981.49 ± 3.99
Functional Well-being (FW), Baseline18.66 ± 6.1918.76 ± 5.98
FW Change, Cycle 3 Day 1-0.30 ± 5.30-0.07 ± 5.24
FW Change, End Induction0.44 ± 5.630.93 ± 5.85
FW Change, Maint Month 21.04 ± 5.311.25 ± 6.02
FW Change, Maint Month 121.84 ± 5.541.65 ± 5.95
FW Change, End Maint1.40 ± 6.121.72 ± 6.16
SecondaryChange From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)

The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.

Time frame:
Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Reported as:
Mean · units on a scale
Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)
units on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
TOI Score, Baseline86.61 ± 18.1686.94 ± 18.05
TOI Score Change, Cycle 3 Day 10.46 ± 15.032.18 ± 15.95
TOI Score Change, End Induction2.91 ± 17.004.57 ± 16.71
TOI Score Change, Maint M26.22 ± 16.167.17 ± 16.57
TOI Score Change, Maint M127.61 ± 15.627.20 ± 16.75
TOI Score Change, End Maint6.23 ± 17.067.44 ± 16.96
SecondaryChange From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)

The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.

Time frame:
Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Reported as:
Mean · units on a scale
Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)
units on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Lymphoma, Baseline45.01 ± 9.3745.54 ± 9.29
Lymphoma Change, Cycle 3 Day 12.04 ± 7.182.71 ± 7.46
Lymphoma Change, End Induction2.99 ± 8.633.01 ± 8.36
Lymphoma Change, Maint Month 24.80 ± 8.294.52 ± 8.32
Lymphoma Change, Maint Month 124.93 ± 8.344.27 ± 8.31
Lymphoma Change, End Maint4.31 ± 8.814.57 ± 8.54
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)

The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.

Time frame:
Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)
units on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Total Score, Baseline127.40 ± 22.43128.42 ± 22.16
Total Score Change, Cycle 3 Day 11.98 ± 17.013.21 ± 17.12
Total Score Change, End Induction4.18 ± 19.755.10 ± 20.03
Total Score Change, Maint Month 28.40 ± 19.168.13 ± 19.80
Total Score Change, Maint Month 128.87 ± 19.317.90 ± 19.55
Total Score Change, End Maint7.43 ± 19.888.80 ± 20.57
SecondaryChange From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs.

Time frame:
Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Reported as:
Mean · units on a scale
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
units on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Baseline Induction0.80 ± 0.240.81 ± 0.21
Change Baseline, Cycle 3 Day 10.03 ± 0.210.03 ± 0.20
Change Baseline, Induction Compl0.04 ± 0.230.03 ± 0.22
Change Baseline, Maint/Obs Month 20.05 ± 0.230.06 ± 0.22
Change from Baseline, Maint/Obs Month 120.00 ± 0.00-0.20 ± NA
Change Baseline, Maint/Obs Completion—-0.10 ± NA
SecondaryChange From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit.

Time frame:
Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Reported as:
Mean · units on a scale
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase
units on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Change Baseline, Maint/Obs Month 20.04 ± 0.340.04 ± 0.14
Change Baseline, Maint/Obs Month 120.06 ± 0.240.06 ± 0.21
Change Baseline, Maint/Obs Completion0.03 ± 0.230.05 ± 0.23
SecondaryChange From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit.

Time frame:
Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 after Day 1 of last induction cycle, Follow-up: every year for up to data cut-off (up to 5 years and 2 months)
Reported as:
Mean · units on a scale
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase
units on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Change Baseline, Follow-Up Month 360.05 ± 0.240.06 ± 0.23
Change Baseline, Follow-Up Month 480.05 ± 0.200.06 ± 0.23

Adverse events

Collected over Baseline up to 10 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab+Chemotherapy111/692 (16%)309/692 (44.7%)675/692 (97.5%)
Obinutuzumab+Chemotherapy104/698 (14.9%)361/698 (51.7%)690/698 (98.9%)
Most frequent serious events
Showing 10 of 443
Most frequent serious events
EventRituximab+ChemotherapyObinutuzumab+Chemotherapy
PNEUMONIAInfections and infestations43/69251/698
PYREXIAGeneral disorders23/69237/698
FEBRILE NEUTROPENIABlood and lymphatic system disorders23/69236/698
INFUSION RELATED REACTIONInjury, poisoning and procedural complications19/69236/698
NEUTROPENIABlood and lymphatic system disorders33/69228/698
SEPSISInfections and infestations9/69214/698
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations9/69213/698
DIARRHOEAGastrointestinal disorders7/69211/698
INFECTIONInfections and infestations10/6926/698
ABDOMINAL PAINGastrointestinal disorders6/69210/698
Most frequent other events
Showing 10 of 67
Most frequent other events
EventRituximab+ChemotherapyObinutuzumab+Chemotherapy
INFUSION RELATED REACTIONInjury, poisoning and procedural complications347/692416/698
NAUSEAGastrointestinal disorders338/692354/698
NEUTROPENIABlood and lymphatic system disorders307/692348/698
FATIGUEGeneral disorders277/692275/698
CONSTIPATIONGastrointestinal disorders221/692249/698
COUGHRespiratory, thoracic and mediastinal disorders185/692221/698
DIARRHOEAGastrointestinal disorders168/692207/698
PYREXIAGeneral disorders150/692200/698
VOMITINGGastrointestinal disorders151/692182/698
HEADACHENervous system disorders123/692155/698

Baseline characteristics

The intent-to treat (ITT) population was defined as all randomized participants grouped according to their randomized treatment arm regardless of what treatments were actually received.

Age, Continuous
Age, Continuous(years)Rituximab+Chemotherapy - Induction PeriodObinutuzumab+Chemotherapy - Induction PeriodTotal
Mean58.1 ± 12.358.9 ± 11.658.5 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab+Chemotherapy - Induction PeriodObinutuzumab+Chemotherapy - Induction PeriodTotal
Female374365739
Male325337662
Age Continuous in Follicular Lymphoma Sub-Population
Age Continuous in Follicular Lymphoma Sub-Population(years)Rituximab+Chemotherapy - Induction PeriodObinutuzumab+Chemotherapy - Induction PeriodTotal
Mean57.7 ± 12.258.2 ± 11.557.9 ± 11.9
Gender in Follicular Lymphoma Sub-Population
Gender in Follicular Lymphoma Sub-Population(Participants)Rituximab+Chemotherapy - Induction PeriodObinutuzumab+Chemotherapy - Induction PeriodTotal
Female321318639
Male280283563
08

Study locations

183 sites
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
  • The Regents of the University of California; Office of Research
    Irvine, California 92697, United States
  • Kootenai Cancer Center
    Post Falls, Idaho 83854, United States
  • Illinois Cancer Care, P.C. - Galesburg
    Galesburg, Illinois 61401, United States
  • Siouxland Hematology/Oncology
    Sioux City, Iowa 51101, United States
  • University of Kansas; Medical Center & Medical pavilion
    Westwood, Kansas 66205, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214-3728, United States
  • Mercy Medical Research Institute
    Springfield, Missouri 65807, United States
  • MT Cancer Inst Fndtn; MT Can Spec
    Missoula, Montana 59802, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Providence St. Vincent Medical Center
    Portland, Oregon 97225, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • Concord Repatriation General Hospital; Haematology
    Sydney, New South Wales 2139, Australia
  • Westmead Hospital; Haematology
    Sydney, New South Wales 2145, Australia
  • Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology
    Woolloongabba, Queensland 4102, Australia
  • St Vincent'S Hospital; Haematology
    Fitzroy, Victoria 3065, Australia
  • Peter MacCallum Cancer Centre; Department of Haematology
    Melbourne, Victoria 3002, Australia
  • Austin and Repatriation Medical Centre; Cancer Services
    Melbourne, Victoria 3084, Australia
  • Monash Medical Centre; Haematology
    Melbourne, Victoria 3168, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • UZ Gent
    Gent, 9000, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Tom Baker Cancer Centre-Calgary
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Dr. Georges L. Dumont University Hospital Centre
    Moncton, New Brunswick E1C 8X3, Canada
  • Ottawa General Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • North York General Hospital
    Toronto, Ontario M2K 1E1, Canada
  • Humber River Hospital
    Toronto, Ontario M3M 0B2, Canada
  • Toronto East General Hospital; Haematology/Oncology
    Toronto, Ontario M4C 3E7, Canada
  • Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie
    Greenfield Park, Quebec J4V 2H1, Canada
  • Peking University First Hospital
    Beijing City, 100034, China
  • Cancer Hospital Chinese Academy of Medical Sciences.
    Beijing, 100021, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • General Hospital of Chinese PLA; Department of Hematology
    Beijing, 100853, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • Fujian Medical University Union Hospital
    Fuzhou City, 350001, China
  • Sun Yet-sen University Cancer Center
    Guangzhou, 510060, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Jiangsu Cancer Hospital
    Nanjing City, 211100, China
  • Jiangsu Province Hospital
    Nanjing, 210036, China
  • Fudan University Shanghai Cancer Center
    Shanghai City, 200120, China
  • Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
    Shanghai, 200025, China
  • Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center
    Wuhan, 430023, China
  • Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • Fn Hr. Kralove; IV. Interni Hematologicka Klinika
    Hradec Kralove, 500 05, Czechia
  • Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
    Praha 2, 128 08, Czechia
  • Helsinki University Central Hospital; Dept of Oncology
    Helsinki, 00250, Finland
  • Hotel Dieu; Medecine D
    Angers, 49933, France
  • Hopital Augustin Morvan; Hematologie
    Brest, 29609, France
  • Chu Estaing; Hematologie Clinique Adultes
    Clermont Ferrand, 63003, France
  • Clinique Victor Hugo
    LeMans, 72000, France
  • Hopital De La Conception; Hematologie Clinique
    Marseille, 13005, France
  • Hopital Saint Eloi; Hematologie Oncologie Medicale
    Montpellier, 34295, France
  • Hopital Saint Jean; Hematologie
    Perpignan, 66046, France
  • Onkologischer Schwerpunkt am Oskar-Helene-Heim; Dres. Herrenberger, Keitel-Wittig u. Kirsch
    Berlin, 14195, Germany
  • Klinikum Chemnitz gGmbH Krankenhaus Küchwald Klinik f.Innere Medizin III
    Chemnitz, 09113, Germany
  • Städtisches Klinikum Dessau
    Dessau-Roßlau, 06847, Germany
  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
    Dresden, 01307, Germany
  • Gemeinschaftspraxis Dr. med. J. Mohm und Dr. med. G. Prange-Krex; Fachaerzte fuer Innere Medizin
    Dresden, 01307, Germany
  • HELIOS Klinikum Erfurt I.Medizinische Klinik
    Erfurt, 99089, Germany
  • St.-Antonius-Hospital gGmbH; Klinik für Hämatologie und Onkologie
    Eschweiler, 52249, Germany
  • Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung
    Essen, 45122, Germany
  • Klinik Johann Wolfgang von Goethe Uni; Medizinische Klinik II
    Frankfurt, 60596, Germany
  • Universitätsklinikum Freiburg; Klinik für Innere Medizin I; Hämatologie/Onkologie
    Freiburg, 79106, Germany
  • Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik
    Greifswald, 17475, Germany
  • Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie
    Göttingen, 37075, Germany
  • Kath. Krankenhaus Hagen gem. GmbH, St.-Josefs-Hospital; Klinik für Hämatologie und Onkologie
    Hagen, 58097, Germany
  • Onkologische Schwerpunktpraxis Dres. Bernd Gaede, Hans-Ulrich Ehlers, Ulrike Rodewig u.w.
    Hannover, 30171, Germany
  • Dres.Andreas Karcher und Stefan Fuxius
    Heidelberg, 69115, Germany
  • Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V
    Heidelberg, 69120, Germany
  • Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I
    Homburg/Saar, 64421, Germany
  • Universitätsklinikum Jena; Klinik für Innere Medizin II
    Jena, 07747, Germany
  • UKSH, Campus Kiel; Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie
    Kiel, 24105, Germany
  • Institut für Versorgungsforschung in der Onkologie GbR Koblenz
    Koblenz, 56068, Germany
  • Klinik der Uni zu Köln; Klinik für Innere Medizin
    Köln, 50924, Germany
  • Tagesklinik Landshut; Hämatologie/Onkologie
    Landshut, 84028, Germany
  • Gemeinschaftspraxis für Hämatologie und Onkologie
    Lebach, 66822, Germany
  • Klinikum St.Georg gGmbH Klinik für Internistische Onkologie und Hämotologie
    Leipzig, 04129, Germany
  • Klinikum der Stadt Ludwigshafen; Medizinische Klinik A
    Ludwigshafen, 67063, Germany
  • Onkologische Gemeinschaftspraxis
    Magdeburg, 39104, Germany
  • Otto von Guericke Uni Magdeburg Uniklinik; Hämatologie/Onkologie
    Magdeburg, 39120, Germany
  • Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik
    Mainz, 55131, Germany
  • Mannheimer Onkologie Praxis Dres. Jürgen Brust Dieter Schuster
    Mannheim, 68161, Germany
  • Klinikum Mannheim III. Medizinische Klinik
    Mannheim, 68167, Germany
  • Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin
    Mutlangen, 73557, Germany
  • St. Frankziskus Krankenhaus, Med. Klinik I; Klinik für Hämatologie,Onkologie u. Gastroenterologie
    Mönchengladbach, 41063, Germany
  • Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III
    München, 81377, Germany
  • Klinikum rechts der Isar der TU München; III. Medizinischen Klinik (Hämatologie/Onkologie)
    München, 81675, Germany
  • Gemeinschaftspraxis Dr. med. Holger Klaproth
    Neunkirchen/Saar, 66538, Germany
  • Pius-Hospital; Klinik fuer Haematologie und Onkologie
    Oldenburg, 26121, Germany
  • Brüderkrankenhaus St. Josef
    Paderborn, 33098, Germany
  • Prosper-Hospital, Medizinische Klinik I
    Recklinghausen, 45659, Germany
  • Krankenhaus Barmherziger Brüder; Klinik für Internistische Onkologie / Hämatologie
    Regensburg, 93049, Germany
  • Praxis für Hämatologie & Onkologie
    Saarbruecken, 66113, Germany
  • Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie
    Trier, 54292, Germany
  • Universität Tübingen; Med. Klinik; Innere Medizin I
    Tübingen, 72076, Germany
  • Universtitätsklinikum Ulm; Klinik für Innere Medizin III
    Ulm, 89081, Germany
  • Helios Dr. Horst Schmidt Kliniken; Klinik Innere MED III: Hämatologie, Onkologie, Palliativmedizin
    Wiesbaden, 65199, Germany
  • Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker
    Würzburg, 97080, Germany

Showing the first 100 of 183 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Casulo C, Herold M, Hiddemann W, Iyengar S, Marcus RE, Seymour JF, Launonen A, Knapp A, Nielsen TG, Mir F. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):40-48. doi: 10.1016/j.clml.2022.09.003. Epub 2022 Oct 4. PubMed 36379880 ↗
  • Hong X, Song Y, Shi Y, Zhang Q, Guo W, Wu G, Li J, Feng J, Kinkolykh A, Knapp A, Lin T. Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study. Chin Med J (Engl). 2021 Sep 16;135(4):433-440. doi: 10.1097/CM9.0000000000001737. PubMed 35194005 ↗
  • Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trneny M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcgamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985. PubMed 34323957 ↗
  • Davies A, Trask P, Demeter J, Florschutz A, Hanel M, Kinoshita T, Pettengell R, Quach H, Robinson S, Sadullah S, Sancho JM, Udvardy M, Witzens-Harig M, Knapp A, Liu W. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Ann Hematol. 2020 Dec;99(12):2837-2846. doi: 10.1007/s00277-020-04021-6. Epub 2020 Apr 20. PubMed 32314038 ↗
  • Klanova M, Oestergaard MZ, Trneny M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3. PubMed 31053601 ↗
  • Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19. PubMed 30341058 ↗
  • Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptacnik V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8. Erratum In: Lancet Oncol. 2019 Jun;20(6):e293. doi: 10.1016/S1470-2045(19)30280-3. PubMed 30309758 ↗
  • Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Durig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1. PubMed 29856692 ↗
  • Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trneny M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. PubMed 28976863 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Feb 2016, 54 months.

Results were first posted in Jun 2017, 1 year 4 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 54 months is below that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2011
First posted
Apr 11, 2011
StartActual
Jul 6, 2011
Primary completionActual
Feb 1, 2016
CompletionActual
Jul 30, 2021
Results first posted
Jun 7, 2017
Last update
Aug 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01332968
Lead sponsor
Hoffmann-La Roche
Collaborators
German Low Grade Lymphoma Study Group, Institute of Cancer Research, United Kingdom
Responsible party
Sponsor
First posted
Apr 11, 2011
Start date
Jul 6, 2011
Primary completion
Feb 1, 2016
Completion
Jul 30, 2021
Results posted
Jun 7, 2017
Last update
Aug 11, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion